Navigation Links
The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Date:3/18/2012

Microglia are the first line defence of the brain and are constantly looking for infections to fight off. Overactive microglia can cause uncontrolled inflammation within the brain, which can in turn lead to neuronal damage. New research published in BioMed Central's open access journal Journal of Neuroinflammation shows that, honokiol (HNK) is able to down-regulate the production of pro-inflammatory cytokines and inflammatory enzymes in activated microglia via Klf4, a protein known to regulate DNA.

Scientists from the National Brain Research Centre, Manesar, India, used lipopolysaccharide (LPS), a molecule present on the surface of bacteria, to stimulate an immune response from microglia cells. LPS mimics the effect of a bacterial infection and the microglia cells spring into action, releasing proinflammatory cytokines, such as TNFa.

Activation of microglia also stimulates the production of nitric oxide (NO) and Cox-2, which co-ordinate the immune response, leading to inflammation. However uncontrolled inflammation can lead to neuronal death and permanent brain damage. Microglial inflammation is also observed in several neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

The team led by Dr Anirban Basu found that the inflammatory response was mediated by Klf4, a 'transcription' factor which binds directly to DNA to enhance or impede gene expression. Treating microglia with HNK reduced their activation and HNK treated cells secreted less cytokines in response to LPS. HNK also down regulated the activity of Klf4 (and pNF-kb - another regulator of inflammation).

Dr Basu suggested that HNK down regulates Klf4 which in turn down regulates NO and Cox-2 production. He said, "HNK can easily move across the blood brain barrier and we found that HNK reduced levels of pNF-kb and Klf4 as well as the number of activated microglia in the brains of LPS treated mice."

He continued, "Our work with HNK has found that Klf4 is an important regulator of inflammation. Both HNK and Klf4 may be important not only in regulating inflammation due to infection, but may also have applications in other diseases which affect the brain and nervous system."


'/>"/>

Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-203-192-2370
BioMed Central
Source:Eurekalert

Related biology news :

1. Springer and Japanese Society of Biorheology to work together
2. Geraniums could help control devastating Japanese beetle
3. Japanese gourmet mushroom found in Sweden
4. UCLA, Japanese company to collaborate on specialized nano-imaging instrumentation
5. Japanese researchers report on liver transplantation studies using animal and iPS cells
6. Moessbauer group of Mainz University preparing for participation in Japanese moon mission
7. Genome-wide study reveals 3 new susceptibility loci for adult asthma in Japanese population
8. Bulletin of the Atomic Scientists publishes Japanese translation of special Fukushima issue
9. Balance between traditional activities, tourism key to sustaining coastal Alaska communities
10. Traditional Dutch landscape under threat
11. Stroke Belt deaths tied to non-traditional risk factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 2017 Patient Care services ... telemedicine application, new and leading edge therapies and ... boom worldwide. The healthcare sector as whole continues ... and new therapies for companies such as Reliq ... Biosciences, Inc. (NASDAQ: CLRB ), Cytori ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, today ... 1a financing and entered into a $5 million ... intends to use the capital for general corporate ... advancements in the treatment of serious diseases treated ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
Breaking Biology Technology: